Issue

Vol. 36 No. 2 (2024): Vol 36 Issue 2, 2024

Copyright (c) 2024 Srinivasa Rao Katta

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Characterization of Degradation Products of Selpercatinib by Mass Spectrometry: Optimization of Stability-Indicating HPLC Method for Separation and Quantification of Process Related Impurities of Selpercatinib

https://doi.org/10.14233/ajchem.2024.30884
Srinivasa Rao Katta
Department of Chemistry, Radha Govind University, Ramgarh-829122, India
Gajanand Thakre
Department of Chemistry, Radha Govind University, Ramgarh-829122, India

Corresponding Author(s) : Srinivasa Rao Katta

katta.srinivasmsc@gmail.com

Asian Journal of Chemistry, Vol. 36 No. 2 (2024): Vol 36 Issue 2, 2024

Abstract

The study aimed to investigate a novel approach by utilizing liquid chromatography in coupled with mass spectrometry (LC-MS) to resolve, analyze and characterize significantly less quantity of stress degradation products (DPs) of selpercatinib along with its process related impurities. The analytes resolved on ZORBAX Eclipse (250 mm) stationary phase that was maintained employing 0.5 M sodium perchlorate at pH 5.4 methanol and acetonitrile in 50:20:30 (v/v) pumped at 0.8 mL/min isocratic flow and 241 nm wavelength. The method produces very high correlate linear curve in 30-240 μg/mL for selpercatinib and 0.03-0.24 μg/mL for its impurities with significantly low detection limit of 0.01 μg/mL for impurities. Selpercatinib pure compound was subjected to stress studies and chromatographic results confirm the formation of four DPs, which were characterized with the interpretation of their mass fragmentation pattern. The DPs were identified as 6-hydroxy-4-(6-(6-((6-methoxypyridin3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (DP 1), 6′-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,2-dihydro-[3,3′-bipyridin]-5-ol (DP 2), (6-hydroxy-4-(6-(6-(pyridin-3-ylmethyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (DP 3), 1-amino-6′-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-1,2-dihydro-[3,3′-bipyridin]-5-ol (DP 4), 6-(2-hydroxy-2-methyl-propoxy)-4-(6-(3-methylpiperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (DP 5) and 6-(2-hydroxy-2-methyl-propoxy)-4-(6-(3-methylpiperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile (DP 6). Based on findings, it was concluded that this method was effectively applied for the regular quantification of impurities of selpercatinib in formulations. Additionally, it demonstrated applicability for the identification of both known and unknown impurities of selpercatinib.

Keywords

Selpercatinib Impurity analysis Degradation studies Degradation products Mass spectral characterization
Katta, S. R., & Thakre, G. (2024). Characterization of Degradation Products of Selpercatinib by Mass Spectrometry: Optimization of Stability-Indicating HPLC Method for Separation and Quantification of Process Related Impurities of Selpercatinib. Asian Journal of Chemistry, 36(2), 341–352. https://doi.org/10.14233/ajchem.2024.30884
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. S.R. Melo, M. Homem-de-Mello, D. Silveira and L.A. Simeoni, J. Pharm. Sci. Technol., 68, 221 (2014).
  2. S. Singh, M. Junwal, G. Modhe, H. Tiwari, M. Kurmi, N. Parashar and P. Sidduri, Trends Analyt. Chem., 49, 71 (2013); https://doi.org/10.1016/j.trac.2013.05.006
  3. K. Alsante, A. Ando, R. Brown, J. Ensing, T. Hatajik, W. Kong and Y. Tsuda, Adv. Drug Deliv. Rev., 59, 29 (2007); https://doi.org/10.1016/j.addr.2006.10.006
  4. M. Blessy, R.D. Patel, P.N. Prajapati and Y.K. Agrawal, J. Pharm. Anal., 4, 159 (2014); https://doi.org/10.1016/j.jpha.2013.09.003
  5. World Health Organization, Stability Testing of Active Pharmaceutical Ingredients and Finished Pharmaceutical Products, Geneva: Switzerland (2009).
  6. International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, Stability Testing of New Drug Substances and Products Q1A(R2): Geneva, Switzerland (2000).
  7. F. Qiu and D.L. Norwood, J. Liq. Chromatogr. Relat. Technol., 30, 877 (2007); https://doi.org/10.1080/10826070701191151
  8. A.Y. Li, M.G. McCusker, A. Russo, K.A. Scilla, A. Gittens, R. Mehra, K. Arensmeyer, V. Adamo and C. Rolfo, Cancer Treat. Rev., 81, 101911 (2019); https://doi.org/10.1016/j.ctrv.2019.101911
  9. A. Russo, A.R. Lopes, M.G. McCusker, S.G. Garrigues, G.R. Ricciardi, K.E. Arensmeyer, K.A. Scilla, R. Mehra and C. Rolfo, Curr. Oncol. Rep., 22, 48 (2020); https://doi.org/10.1007/s11912-020-00909-8
  10. B.J. Solomon, L. Tan, J.J. Lin, S.Q. Wong, S. Hollizeck, K. Ebata, B.B. Tuch, S. Yoda, J.F. Gainor, L.V. Sequist, G.R. Oxnard, O. Gautschi, A. Drilon, V. Subbiah, C. Khoo, E.Y. Zhu, M. Nguyen, D. Henry, K.R. Condroski, G.R. Kolakowski, E. Gomez, J. Ballard, A.T. Metcalf, J.F. Blake, S.J. Dawson, W. Blosser, L.F. Stancato, B.J. Brandhuber, S. Andrews, B.G. Robinson and S.M. Rothenberg, J. Thorac. Oncol., 15, 541 (2020); https://doi.org/10.1016/j.jtho.2020.01.006
  11. N. Singamsetty and R. Sundararajan, Int. J. Res. Pharm. Sci., 12, 931 (2021); https://doi.org/10.26452/ijrps.v12i1.4471
  12. J.L. Gulikers, A.J. van Veelen, E.M.J. Sinkiewicz, Y.M. de Beer, M. Slikkerveer, L.M.L. Stolk, V.C.G. Tjan-Heijnen, L.E.L. Hendriks, S. Croes and R.M.J.M. van Geel, Biomed. Chromatogr., 37, e5628 (2023); https://doi.org/10.1002/bmc.5628
  13. International Conference of Harmonisation (ICH), Q1A(R2), Stability Testing of New Drug Substances and Products. Geneva: International Conference on Harmonization (2003).
  14. International Conference of Harmonisation (ICH), Q1B, Stability Testing: Photostability Testing of New Drug Substances and Products, Geneva: International Conference on Harmonization (1996).
  15. International Conference of Harmonisation (ICH) Q2(R1), Validation of Analytical Procedures: Text and Methodology, Geneva: International Conference on Harmonization (1994).
  16. R.B. Varma and B.S. Rao, Res. J. Pharm. Technol., 15, 5158 (2022); https://doi.org/10.52711/0974-360X.2022.00868
  17. B.H.R. Varma and B.S. Rao, Res. J. Chem. Environ., 27, 54 (2023); https://doi.org/10.25303/2702rjce054061
  18. V.B. Rajesh, S.R. Battula, M.V.N.R. Kapavarapu and V.R. Mandapati, Rasayan J. Chem., 15, 2373 (2022); https://doi.org/10.31788/RJC.2022.1547008
  19. V.B. Rajesh, R.B. Sreenivasa, V.N.R.K. Maruthi and R.M. Varaprasad, Ann. Pharm. Fr., 81, 64 (2023); https://doi.org/10.1016/j.pharma.2022.06.012
  20. B.K. Bikshal, R.A. Venkateswara and R.M. Useni, Indian Drugs, 55, 41 (2018); https://doi.org/10.53879/id.55.12.11185
  21. K.S. Girija, B.B. Kasimala and V.R. Anna, Int. J. Appl. Pharm., 13, 165 (2021); https://doi.org/10.22159/ijap.2021v13i2.39895
  22. B.K. Bikshal, R.M. Useni, R.A. Venkateswara and R.L. Maheshwara, Thai J. Pharm. Sci., 42, 27 (2018).
  23. U.R. Mallu, V.R. Anna and B.B. Kasimala, Turk. J. Pharm. Sci., 16, 457 (2019); https://doi.org/10.4274/tjps.galenos.2018.34635
Read More
Author biographies is not available.
Download
AJC-36-2-10
Statistic
Read Counter : 1 Download : 0